Interleukin-4 treatment reduces leukemia burden in acute myeloid leukemia.

ABSTRACT: Interleukin-4 (IL-4) is a signature cytokine pivotal in Type 2 helper T cell (Th2) immune response, particularly in allergy and hypersensitivity. Interestingly, IL-4 increases endogenous levels of prostaglandin D₂ (PGD₂ ) and its metabolites, Δ¹² -prostaglandin J₂ (Δ¹² -PGJ₂ ) and 15-deoxy-Δ^12,14 -prostaglandin J₂ (15d-PGJ₂ ), collectively called cyclopentenone PGs (CyPGs). However, the therapeutic role of IL-4 in hematologic malignancies remains unclear. Here, we employed a murine model of acute myeloid leukemia (AML), where human MLL-AF9 fusion oncoprotein was expressed in hematopoietic progenitor cells, to test the effect of IL-4 treatment in vivo. Daily intraperitoneal treatment with IL-4

SUBMITTER: Qian F 

PROVIDER: S-EPMC9994642 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature